Core Insights - Kronos Bio, Inc. presented new preclinical data on istisociclib (KB-0742), a CDK9 inhibitor, demonstrating its potential to induce cell death in platinum and PARP-inhibitor resistant ovarian cancer models [1][3] - The company is currently conducting a Phase 1/2 clinical trial to evaluate istisociclib's efficacy as a single agent in platinum-resistant high-grade serous ovarian cancer (HGSOC) [2] Preclinical Findings - Istisociclib triggered apoptosis and cell death, evidenced by the accumulation of γH2AX, a marker of DNA damage [4] - The drug disrupted homologous recombination DNA repair by downregulating BRCA1 and RAD51, creating a "BRCAness" phenotype in resistant ovarian cancer cells [4] Clinical Trial Insights - New pharmacokinetic/pharmacodynamic (PK/PD) results from the ongoing trial showed that istisociclib administered at 80mg on a 4 days on/3 days off schedule resulted in a long half-life of approximately 24 hours [4] - Clinical exposures were consistent with efficacious levels observed in preclinical models, leading to sustained downregulation of CDK9-dependent genes in peripheral blood mononuclear cells (PBMCs) [4] Company Overview - Kronos Bio is focused on developing small molecule therapeutics targeting deregulated transcription, a key feature of cancer and other diseases [5] - The company has a preclinical pipeline and two drug candidates, including istisociclib targeting CDK9 and KB-9558 targeting p300 for multiple myeloma [5]

Core Viewpoint - Kronos Bio, Inc. (KRON) has experienced a downtrend with a 5.5% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to analysts' improved earnings forecasts [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2] - KRON's current RSI reading is 23.37, indicating that the heavy selling pressure may be exhausting itself, suggesting a possible trend reversal [5] Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts regarding KRON's earnings estimates, with a 13.9% increase in the consensus EPS estimate over the last 30 days, which often leads to price appreciation [6] - KRON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, indicating a strong potential for a near-term turnaround [7]

SAN MATEO, Calif., and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the following upcoming conferences: H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9–11, 2024 in New York, NY Kronos Bio President and Chief Executive Officer, Norbert Bischofberger, Ph.D., will present on Monday, ...

Kronos Bio, Inc. (KRON) has been on a downward spiral lately with significant selling pressure. After declining 23.5% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whethe ...

Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update — First patient in platinum-resistant high-grade serous ovarian cancer cohort was dosed on optimized dose and schedule with istisociclib (KB-0742); expect data update in 1H 2025 — — KB-9558 IND-enabling studies for multiple myeloma remain on track to be completed in Q4 2024 — — Pipeline update includes an additional indication for KB-9558 in HPV-driven tumors and a separate p300 program focused on autoimmune indications — — $136.6 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to _______ Commission file number: 001-39592 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdicti ...

The market expects Kronos Bio, Inc. (KRON) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if th ...

— Company expects to provide an efficacy update on this expansion cohort in 1H 2025 — "We are excited for the focused expansion of KB-0742 in platinum-resistant HGSOC. KB-0742 has to date provided prolonged stable disease of over 300 days in one of my platinum-resistant HGSOC patients," said Howard "Skip" A. Burris M.D., president of Sarah Cannon Research Institute (SCRI). "HGSOC patients have limited treatment options after progressing on platinum therapy and KB-0742 brings new possibilities to those battl ...

— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — — Company expects to provide an efficacy update on this expansion cohort in 1H 2025 — SAN MATEO, Calif. and CAMBRIDGE, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the first patient dosed in an expansion cohort with KB-0742 at a dose of 80 ...

Title: Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors Presenter: Brian A. Van Tine, M.D., Ph.D., Washington University in St. Louis Abstract ID#: 3102 Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Location: Hall A, McCormick Place, Chicago, Illinois — KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed — SAN MATEO, Calif. and ...